



September 27, 2023

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai - 400 001

Sub: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions, if any, of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Company plans to source injections portfolio of its products from a contract manufacturer, hence the Company shall discontinue production of injections at its manufacturing plant in Goa effective September 30, 2023.

The injections portfolio, procured from the Company's manufacturing facility at Goa, accounted for revenue of Rs. 102.92 crores during the financial year 2022-23, constituting 8.37% of the Company's total revenue. Discontinuation of production at Company's plant in Goa, shall not have an impact on continuity of sale of injections by the Company, as the products will be sourced from a contract manufacturer.

The Company is outsourcing manufacturing of the injections portfolio, with an intent to achieve cost efficiency and supply optimization.

Thanking you,

For *Procter & Gamble Health Limited*

Zeal Rupani
Company Secretary